美國東部時間2022年06月22日下午02:57(MT Newswres)--全球迷幻藥物開發和交付領域的全球參與者--野外旅行健康有限公司(多倫多證券交易所和納斯達克股票代碼:FTRP)周三宣佈,它已收到納斯達克股票市場有限責任公司的書面通知,通知該公司,該公司不符合納斯達克規則中規定的在納斯達克全球精選市場繼續上市的最低投標價格要求。
熱門資訊> 正文
2022-06-23 02:58
02:57 PM EDT, 06/22/2022 (MT Newswires) -- Field Trip Health Ltd. (TSX and Nasdaq: FTRP), a global player in the development and delivery of psychedelic therapies, announced Wednesday that it has received written notification from The Nasdaq Stock Market LLC notifying the company that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Rules for continued listing on the Nasdaq Global Select Market.
美國東部時間2022年06月22日下午02:57(MT Newswres)--全球迷幻藥物開發和交付領域的全球參與者--野外旅行健康有限公司(多倫多證券交易所和納斯達克股票代碼:FTRP)周三宣佈,它已收到納斯達克股票市場有限責任公司的書面通知,通知該公司,該公司不符合納斯達克規則中規定的在納斯達克全球精選市場繼續上市的最低投標價格要求。
Separately, FTRP plans to release financial results for its fiscal fourth quarter and full year ended March 31, 2022, after market close on Wednesday, June 29, 2022.
另外,FTRP計劃在2022年6月29日星期三收盤后發佈截至2022年3月31日的第四財季和全年財務業績。
On the Nasdaq notification, Listing Rules require listed securities to maintain a minimum bid price of US$1.00 per share, and further provide that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the closing bid price of the company's common shares for the 30 consecutive business days from May 4, 2022, to June 15, 2022, the company no longer meets the minimum bid price requirement.
在納斯達克通知上,上市規則要求上市證券維持最低買入價為每股1美元,並進一步規定,如果短板持續連續30個工作日,則存在未能達到最低買入價要求的行為。以公司普通股自2022年5月4日至2022年6月15日連續30個工作日的收盤價計算,公司不再滿足最低投標價格要求。
The Notification Letter does not impact the company's listing on the Nasdaq Global Select Market at this time. In accordance with Nasdaq Listing Rules, the company has 180 calendar days, or until December 13, 2022, to regain compliance by virtue of its common shares having a closing bid price of at least US$1.00 for a minimum of 10 consecutive business days. In the event the company does not regain compliance by December 13, 2022, it may be eligible for additional time to regain compliance or may face delisting.
該通知函不影響該公司目前在納斯達克全球精選市場的上市。根據納斯達克上市規則,該公司有180個歷日,即到2022年12月13日,憑藉其普通股在最少連續10個工作日的收盤價至少為1.00美元的情況下重新獲得合規。如果該公司在2022年12月13日之前沒有重新獲得合規,它可能有資格獲得額外的合規時間,或者可能面臨退市。
As previously announced, the company intends to consolidate its common shares on a ratio of between 5 and 1 pre-consolidation common share for each pre-consolidation common share as part of the spin out transaction expected to close in early August and, therefore, anticipates that the deficiency will be cured within the prescribed compliance period. The consolidation is subject to shareholder approval at a special meeting of shareholders to be held on June 27, 2022.
正如之前宣佈的那樣,作為預計於8月初完成的分拆交易的一部分,該公司打算將其普通股合併,合併前普通股與合併前普通股的比率為5至1股,因此,預計不足之處將在規定的合規期內得到彌補。此次合併還需在2022年6月27日舉行的股東特別大會上獲得股東批准。
The company expects that its common shares will continue to be listed and trade on the Nasdaq Global Select Market during these compliance periods. The company said its business operations are not affected by the receipt of the Notification Letter. The company is also listed on the Toronto Stock Exchange and the Notification Letter does not affect the company's compliance status with such listing.
該公司預計,在這些合規期內,其普通股將繼續在納斯達克全球精選市場上市和交易。該公司表示,其業務運營不受收到通知函的影響。該公司也在多倫多證券交易所上市,通知函不影響該公司對此類上市的合規狀況。
Price: 1.07, Change: +0.02, Percent Change: +1.90
價格:1.07,變化:+0.02,變化百分比:+1.90